H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Atreca (BCEL) today and set a price target of $25.00. The company’s shares closed last Wednesday at $9.82, close to its 52-week low of $9.19.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 28.9% and a 48.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Atreca with a $29.67 average price target, which is a 196.7% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $33.00 price target.
See today’s analyst top recommended stocks >>
Based on Atreca’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $23.01 million. In comparison, last year the company had a GAAP net loss of $20.11 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA.